HeartBeam (NASDAQ:BEAT) Director Richard Ferrari Acquires 62,500 Shares of Stock

HeartBeam, Inc. (NASDAQ:BEAT) Director Richard Ferrari purchased 62,500 shares of the business’s stock in a transaction on Thursday, April 16th. The shares were bought at an average price of $0.80 per share, with a total value of $50,000.00. Following the purchase, the director directly owned 291,636 shares in the company, valued at approximately $233,308.80. The trade was a 27.28% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

HeartBeam Stock Performance

Shares of BEAT opened at $0.81 on Friday. The firm has a market capitalization of $33.28 million, a P/E ratio of -1.31 and a beta of -0.63. HeartBeam, Inc. has a 52 week low of $0.54 and a 52 week high of $4.00. The stock has a 50 day moving average price of $1.30 and a two-hundred day moving average price of $1.62.

HeartBeam (NASDAQ:BEAT) last posted its earnings results on Thursday, March 12th. The medical research company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01).

Analyst Ratings Changes

A number of research firms have issued reports on BEAT. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of HeartBeam in a report on Monday, December 29th. HC Wainwright reiterated a “buy” rating and issued a $5.50 target price on shares of HeartBeam in a report on Monday, March 16th. B. Riley Financial initiated coverage on shares of HeartBeam in a report on Tuesday, March 31st. They set a “buy” rating and a $4.00 price target on the stock. D. Boral Capital initiated coverage on shares of HeartBeam in a research report on Friday, March 27th. They issued a “buy” rating and a $5.00 price objective for the company. Finally, Wall Street Zen lowered shares of HeartBeam to a “strong sell” rating in a research note on Saturday, January 3rd. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $4.80.

Trending Headlines about HeartBeam

Here are the key news stories impacting HeartBeam this week:

• Positive Sentiment: Senior insiders (multiple directors and the CFO) purchased a total of ~1.12M shares at $0.80 apiece (roughly $895k in aggregate), including a 750k‑share buy by director Mark E. Strome, signaling management confidence and increasing insider ownership. SEC Filing — Mark E. Strome
• Positive Sentiment: Reported short interest fell ~22.8%, which reduces immediate short‑selling pressure and can support the share price during this post‑offering period. Short interest report
• Neutral Sentiment: Recent analyst/press comparison pieces examine HeartBeam versus peers; useful for longer‑term competitive/contextual perspective but not an immediate catalyst. Competitive comparison
• Negative Sentiment: HeartBeam launched and priced a $10 million public offering to support commercialization and AI initiatives. Equity offerings are dilutive and typically weigh on the share price; media coverage noted the stock slipped after the offering was priced. Offering pricing Offering closing Market reaction article

Institutional Investors Weigh In On HeartBeam

Large investors have recently made changes to their positions in the business. Clarity Financial LLC purchased a new position in shares of HeartBeam in the 4th quarter worth about $25,000. Bessemer Group Inc. purchased a new stake in HeartBeam during the third quarter worth about $25,000. CIBC Private Wealth Group LLC purchased a new stake in HeartBeam during the fourth quarter worth about $26,000. Raymond James Financial Inc. increased its holdings in HeartBeam by 102.2% during the second quarter. Raymond James Financial Inc. now owns 28,178 shares of the medical research company’s stock worth $35,000 after buying an additional 14,242 shares during the last quarter. Finally, Truist Financial Corp purchased a new stake in HeartBeam during the fourth quarter worth about $36,000. 7.77% of the stock is owned by hedge funds and other institutional investors.

About HeartBeam

BioTelemetry, Inc, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in two segments, Healthcare and Research. The Healthcare segment focuses on the remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, memory loop event, and non-loop event monitors.